WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/120512    International Application No.:    PCT/US2005/019568
Publication Date: 22.12.2005 International Filing Date: 03.06.2005
A61K 31/45 (2006.01), A61K 31/47 (2006.01), A61K 35/78, A61K 37/70, A61K 37/72
Applicants: SMITHKLINE BEECHAM (CORK) LIMITED [IE/IE]; Currabinny, Carrigaline, County Cork (IE) (For All Designated States Except US).
BERGER, Mark, S. [US/US]; (US) (For US Only).
GILMER, Tona, Morgan [US/US]; (US) (For US Only).
PANDITE, Arundathy, Nirmalini [US/US]; (US) (For US Only)
Inventors: BERGER, Mark, S.; (US).
GILMER, Tona, Morgan; (US).
PANDITE, Arundathy, Nirmalini; (US)
Agent: DADSWELL, Charles; GlaxoSmithKline, Corporate Intellectual Property Dept, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US)
Priority Data:
60/577,337 04.06.2004 US
Abstract: front page image
(EN)The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and at least one additional anti-neoplastic compound. In particular, the method relates to a methods of treating cancers by administration of N-{3-chloro-4-[(3-fluorobenzyl) oxy]phenyl}-6-[5-({[2-(methanesulphonyl) ethyl]amino} methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof in combination with at least one additional anti-neoplastic compound.
(FR)La présente invention concerne une méthode de traitement d'un cancer chez un mammifère, par administration de 4-quinazolinamines et d'au moins un composé anti-néoplastique complémentaire. On décrit, en particulier, des méthodes de traitement de cancers, par administration de N-{3-chloro-4-[(3-fluorobenzyl) oxy]phényl}-6-[5-({[2-(méthanesulphonyl) éthyl]amino} méthyl)-2-furyl]-4-quinazolinamine et de ses sels et solvates, en association avec au moins un composé anti-néoplastique complémentaire.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)